Shattuck Labs, Inc. STTK
Institutional shares held
28.8 Million
300
calls
1.2K
puts
Total value of holdings
$32.9M
$0
calls
$1K
puts
Market Cap
$48.3M
42,382,000
Shares Out.
Institutional ownership
68.03%
# of Institutions
80
We take great care to ensure that the data presented and summarized in this overview for Shattuck Labs, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STTK
View all-
Prosight Management, LP Dallas, TX5.68MShares$6.47 Million5.32% of portfolio
-
Redmile Group, LLC San Francisco, CA5.62MShares$6.4 Million1.28% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.9MShares$3.31 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$2.82 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.4MShares$2.74 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.57MShares$1.79 Million0.0% of portfolio
-
Clark Estates Inc New York, NY1.48MShares$1.68 Million1.34% of portfolio
-
Geode Capital Management, LLC Boston, MA912KShares$1.04 Million0.0% of portfolio
-
State Street Corp Boston, MA766KShares$873,7070.0% of portfolio
-
Investment Management Of Virginia LLC506KShares$576,8850.29% of portfolio
Latest Institutional Activity in STTK
Top Purchases
Top Sells
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Insider Transactions at STTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
36,500
+33.95%
|
$36,500
$1.21 P/Share
|
|
Jun 28
2024
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
3,000
+1.24%
|
$9,000
$3.9 P/Share
|
|
Jun 27
2024
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
5,416
+2.25%
|
$16,248
$3.89 P/Share
|
|
Jun 26
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
14,400
+29.45%
|
$43,200
$3.47 P/Share
|
|
Jun 04
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,050
+13.17%
|
$9,150
$3.57 P/Share
|
|
May 10
2024
|
Stephen Stout |
SELL
Payment of exercise price or tax liability
|
Direct |
967
-1.3%
|
$9,670
$10.42 P/Share
|
|
Mar 28
2024
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
4,425
-0.08%
|
-
|
|
Mar 06
2024
|
Stephen Stout |
SELL
Open market or private sale
|
Direct |
16,004
-6.41%
|
$160,040
$10.53 P/Share
|
|
Mar 06
2024
|
Stephen Stout |
BUY
Exercise of conversion of derivative security
|
Direct |
11,109
+6.12%
|
$33,327
$3.54 P/Share
|
|
Jan 30
2024
|
Casi De Young Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,008
-2.19%
|
$18,072
$9.99 P/Share
|
|
Jan 30
2024
|
Abhinav A. Shukla Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,290
-2.8%
|
$20,610
$9.99 P/Share
|
|
Jan 30
2024
|
Stephen Stout |
SELL
Payment of exercise price or tax liability
|
Direct |
593
-0.74%
|
$5,337
$9.99 P/Share
|
|
Jan 30
2024
|
Arundathy N. Pandite Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,920
-1.33%
|
$26,280
$9.99 P/Share
|
|
Jan 10
2024
|
Stephen Stout |
BUY
Grant, award, or other acquisition
|
Direct |
49,050
+38.03%
|
-
|
|
Jan 10
2024
|
Abhinav A. Shukla Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,425
+29.03%
|
-
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.6%
|
$250,000
$10.0 P/Share
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,470
-1.23%
|
$24,700
$10.09 P/Share
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,500
+21.95%
|
-
|
|
Jan 10
2024
|
Casi De Young Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,583
-1.7%
|
$15,830
$10.09 P/Share
|
|
Jan 10
2024
|
Casi De Young Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,200
+33.17%
|
-
|
Last 12 Months Summary
Buy / Acquisition
305K
Shares
From
9
Insiders
| Open market or private purchase | 59.3K shares |
|---|---|
| Exercise of conversion of derivative security | 14.2K shares |
| Grant, award, or other acquisition | 232K shares |
Sell / Disposition
61.2K
Shares
From
8
Insiders
| Other acquisition or disposition | 4.43K shares |
|---|---|
| Payment of exercise price or tax liability | 15.8K shares |
| Open market or private sale | 41K shares |